Currently, Transmedics Group Inc [TMDX] is trading at $91.41, up 2.58%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The TMDX shares have gain 10.13% over the last week, with a monthly amount drifted -31.90%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Transmedics Group Inc [NASDAQ: TMDX] stock has seen the most recent analyst activity on October 29, 2024, when Oppenheimer reiterated its Outperform rating and also revised its price target to $125 from $200. Previously, Needham reaffirmed its Buy rating on October 29, 2024, and dropped its price target to $109. On September 24, 2024, Robert W. Baird initiated with a Outperform rating and assigned a price target of $200 on the stock. Needham started tracking the stock assigning a Buy rating and suggested a price target of $208 on August 21, 2024. Cantor Fitzgerald initiated its recommendation with a Overweight and recommended $161 as its price target on June 06, 2024. Stephens started tracking with a Overweight rating for this stock on June 04, 2024, and assigned it a price target of $151. In a note dated March 28, 2024, Piper Sandler initiated an Overweight rating and provided a target price of $95 on this stock.
This stock has fluctuated between a low of $56.83 and a high of $177.37 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $126.75 within the next 12 months. Transmedics Group Inc [NASDAQ: TMDX] shares were valued at $91.41 at the most recent close of the market. An investor can expect a potential return of 38.66% based on the average TMDX price forecast.
Analyzing the TMDX fundamentals
Trailing Twelve Months sales for Transmedics Group Inc [NASDAQ:TMDX] were 401.09M which represents 63.72% growth. Gross Profit Margin for this corporation currently stands at 0.59% with Operating Profit Margin at 0.08%, Pretax Profit Margin comes in at 0.08%, and Net Profit Margin reading is 0.08%. To continue investigating profitability, this company’s Return on Assets is posted at 0.04, Equity is 0.19 and Total Capital is 0.04. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 2.43.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 88.38 points at the first support level, and at 85.35 for the second support level. However, for the 1st resistance point, the stock is sitting at 95.17, and for the 2nd resistance point, it is at 98.93.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Transmedics Group Inc [NASDAQ:TMDX] is 8.20. Also, the Quick Ratio is 7.33, while the Cash Ratio stands at 5.5. Considering the valuation of this stock, the price to sales ratio is 7.65, the price to book ratio is 14.61 and price to earnings (TTM) ratio is 97.93.
Transactions by insiders
Recent insider trading involved Basile Edward M, Director, that happened on Nov 05 ’24 when 6750.0 shares were sold. Chief Commercial Officer, Khayal Tamer I completed a deal on Nov 01 ’24 to sell 1083.0 shares. Meanwhile, Director EDWARD BASILE bought 6750.0 shares on Nov 05 ’24.
